MedWatch

Sales of Biohaven's migraine tablet exceed expectations

Biohaven's tablet for preventive and acute treatment of episodic migraines has surpassed market expectations for the second quarter.

Photo: Kåre Viemose

After Biohaven's migraine drug Nurtec ODT was approved for preventative treatment of episodic migraines in addition to its previous approval as an acute treatment, sales have exploded.

On Wednesday, Biohaven announced that Nurtec has brought USD 93m into the company in Q2, which is almost twice as much as analysts had expected. It's also more than twice as much as the quarter before. Biohaven received secondary approval for the drug in late May.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs